Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is 'cheap' on EV/EBITDA.